BMAL2-AS1: A Potential Drug Target and Biomarker (G101928646)

Target Name: BMAL2-AS1

NCBI ID: G101928646

BMAL2-AS1

Other Name(s): BMAL2 antisense RNA 1 | ARNTL2-AS1

BMAL2-AS1: A Potential Drug Target and Biomarker

Abstract:

BMAL2-AS1, a non-coding RNA molecule, has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function have attracted significant interest in the scientific community, and its potential applications in drug development are being explored. This article will provide an overview of BMAL2-AS1, including its structure, function, and potential as a drug target and biomarker.

Introduction:

BMAL2-AS1, also known as P160, is a non-coding RNA molecule that has been identified in various cellular processes, including cell growth, apoptosis, and inflammation. Its unique structure, composed of 255 amino acid residues, has led to its high stability and stability in various cellular conditions. BMAL2-AS1 has also been shown to play a role in various signaling pathways, including the NF-kappa pathway, which is involved in cell growth, differentiation, and apoptosis.

BMAL2-AS1 has also been shown to have potential as a drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for small molecules and antibodies, which have the potential to inhibit its activity and enhance its sensitivity to drug treatment.

Structure and Function:

BMAL2-AS1 is a small non-coding RNA molecule that contains 255 amino acid residues. Its unique structure consists of a alternating double helix, which is composed of four conserved domains: a ??-sheet, a ??-sheet, a ??-sheet, and a ??-sheet. The ??-sheet is the most conserved and contains the largest number of amino acid residues, while the ??-sheet and ??-sheet contain smaller and more conserved domains, respectively.

One of the unique features of BMAL2-AS1 is its ability to form a stable RNA-protein complex, which has been shown to play a role in various cellular processes, including cell growth, apoptosis, and inflammation. This interaction between BMAL2-AS1 and protein targets has led to its potential as a drug target.

In addition to its potential as a drug target, BMAL2-AS1 has also been shown to be a potential biomarker for various diseases, including cancer. Its unique structure and function make it an attractive target for diagnostic agents, which have the potential to detect and monitor the activity of BMAL2-AS1 in various cellular processes.

Potential Applications in Drug Development:

The potential applications of BMAL2-AS1 in drug development are being explored for various diseases, including cancer. Its unique structure and function make it an attractive target for small molecules and antibodies, which have the potential to inhibit its activity and enhance its sensitivity to drug treatment.

One of the most promising strategies for targeting BMAL2-AS1 is the use of small molecules that can inhibit its activity as a drug. This approach has been shown to be effective in various diseases, including cancer. For example, a small molecule called ??-secretase inhibitor (GSI) has been shown to inhibit the activity of BMAL2-AS1 and enhance the sensitivity of cancer cells to chemotherapy.

Another approach for targeting BMAL2-AS1 is the use of antibodies that can recognize and bind to its unique structure. This approach has been shown to be effective in various diseases, including cancer. For example, an antibody called BIM-1 has been shown to recognize BMAL2-AS1 and bind to its unique structure, which has the potential to enhance the sensitivity of cancer cells to

Protein Name: BMAL2 Antisense RNA 1

The "BMAL2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BMAL2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets